HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
N- (2- (dimethylamino)ethyl)- N- methyl- 4- (2,3,6,7- tetrahydro- 2,6- dioxo- 1,3- dipropyl- 1H- purin- 8- yl)benzenesulfonamide
structure given in first source; purinergic receptor antagonist
Also Known As:
Benzenesulfonamide, N-(2-(dimethylamino)ethyl)-N-methyl-4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-; PD 115199; PD-115199
Networked:
3
relevant articles (
0
outcomes,
1
trials/studies)
Bio-Agent Context: Research Results
Organic Chemicals: 133
Amides: 2428
Sulfonamides: 2809
Benzenesulfonamides: 153
N-(2-(dimethylamino)ethyl)-N-methyl-4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)benzenesulfonamide: 3
Hydrocarbons: 1713
Cyclic Hydrocarbons: 97
Aromatic Hydrocarbons: 291
Benzene Derivatives: 17
Benzenesulfonamides: 153
N-(2-(dimethylamino)ethyl)-N-methyl-4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)benzenesulfonamide: 3
Sulfur Compounds: 278
Sulfones: 534
Sulfonamides: 2809
Benzenesulfonamides: 153
N-(2-(dimethylamino)ethyl)-N-methyl-4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)benzenesulfonamide: 3
Heterocyclic Compounds: 198
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Purines: 651
N-(2-(dimethylamino)ethyl)-N-methyl-4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)benzenesulfonamide: 3
Experts
1.
Beier, N
: 1 article (06/2000)
2.
Gross, G J
: 1 article (06/2000)
3.
Gumina, R J
: 1 article (06/2000)
4.
Schelling, P
: 1 article (06/2000)
Related Diseases
1.
Myocardial Stunning (Stunned Myocardium)
09/01/1997 - "
Similar results were obtained in three other rabbits treated with PD-115199 on day 1. In group II, pretreatment with CCPA during stage II failed to decrease the deficit of WTh on day 1. This study presents a new conscious rabbit model for studying myocardial stunning that is relatively inexpensive and technically less demanding than larger animal models.
"
09/01/1997 - "
In this model, the development of late PC against myocardial stunning is not blocked by nonselective blockade of adenosine receptors with either SPT or PD-115199, nor is it induced by activation of adenosine A1 receptors with CCPA, indicating that adenosine receptors are not involved in the pathogenesis of this phenomenon.
"
2.
Infarction (Infarctions)
05/01/1993 - "
Pretreatment with either the nonselective adenosine receptor antagonist PD 115199 or the selective adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine blocked this protective effect, although in the absence of preconditioning neither of the antagonists affected infarct size.
"
06/01/2000 - "
With an in vivo canine infarct model in which the left anterior descending coronary artery was occluded for 60 min and reperfused for 3 h, neither the K(ATP) channel antagonist glibenclamide nor the adenosine-receptor antagonist PD 115199 attenuated NHE-1 inhibitor-mediated reduction in infarct size expressed as a percentage of the area at risk produced by EMD 85131 (Control, 24.2 +/- 3.6%; EMD 85131, 6.4 +/- 2.3%; PD 115199 + EMD 85131, 6.6 +/- 2.4%; glibenclamide + EMD 85131, 3.5 +/- 1.2%).
"
Related Drugs and Biologics
1.
Purinergic P1 Receptor Antagonists
2.
Adenosine A1 Receptor
3.
Purinergic P1 Receptors (Adenosine Receptor)
4.
Glyburide (Glibenclamide)
5.
Adenosine Triphosphate (ATP)
6.
hydrochloride N- diaminomethylene- 2- methyl- 5- methylsulfonyl- 4- pyrrolobenzamide
7.
1,3-dipropyl-8-cyclopentylxanthine